Comprehensive Program for Hereditary Transthyretin Amyloidosis

Recruiting now

Conditions studied: Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial

In brief

The Comprehensive Program for Hereditary Transthyretin Amyloidosis describes a prospective observational study focused on understanding hereditary transthyretin amyloidosis (ATTR), a progressive and potentially fatal condition marked by amyloid fibril deposits impacting multiple organs. The trial aims to characterize patient phenotypes, investigate factors affecting disease progression, and identify minimum criteria for disease onset. Conducted at Néstor Kirchner Hospital, the trial enrolls participants over 18 years old with confirmed pathogenic TTR variants. It includes thorough evaluations such as genetic testing sponsored by pharmaceutical companies, clinical assessments, and diverse diagnostic tests.

Key facts

Study ID

NCT07213297

Run by

Hospital de Alta Complejidad en Red

People needed

20

Starts

2025-11-01

Expected to finish

2028-12-01

Last updated by the study team

2026-03-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants with a pathogenic variant of the TTR gene (Hereditary Amyloidosis)

You may not qualify if…

• wild-type TTR amyloidosis

Where it is running

• Hospital Cuenca Alta de Cañuelas — Canuelas, Buenos Aires, Argentina (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.